Equities research analysts at StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued to clients and investors on Tuesday. The ...

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report report ...

Holdingannounced that the U.S. Bankruptcy Court for the Southern District of Texas has extended the expiration of the ...

To read more about the latest highlights related to the PDC market, get a snapshot of the key highlights entailed in the ...

Dr. Jerome Zeldis and Dr. Blythe Sather bring exceptional backgrounds in cell therapy and solid tumorsCAMBRIDGE, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ERNA), a leader in cell therapies ...

This page features the latest news about the Sorrento Therapeutics Inc stock. Scilex Holding Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

US Bankruptcy Court for the Southern District of Texas issued an order to extend the lock-up period on the Scilex Dividend Stock, previously distributed by Sorrento, to April 14, 2025.Accordingly, any ...

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), (the "Company" or "PreveCeutical") a health sciences company that develops innovative options for preventive and curative therapies ...

He also brings experience as an executive or board member at NexImmune, Sorrento Therapeutics, Sandoz Research Institute, Janssen Research Institute, PTC Therapeutics, Soligenix, and NexGel.

Shares in Sorrento Therapeutics rose 158% on Friday after it revealed plans to start human trials of an antibody therapy that achieved complete inhibition of the coronavirus in preclinical studies.